Zilucoplan

ATC Code L04AJ06

Zilucoplan

Definition

A synthetic macrocyclic peptide inhibitor of the terminal complement protein C5, with potential anti-inflammatory and cell protective activities. Upon subcutaneous administration, complement zilucoplan binds to a unique site in terminal complement protein C5, which blocks C5 cleavage into C5a and C5b and prevents the C5b-dependent assembly of the membrane-attack complex (MAC). Zilucoplan also inhibits the interaction between C5b and C6, thereby further blocking MAC assembly. This prevents MAC-mediated lysis and destruction of red blood cells (RBCs) that occurs in complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and lupus nephritis (LN). C5, a complement pathway protein, is expressed at high levels by the liver.

Also known as C5 Inhibitor RA101495, Complement C5 Inhibitor RA101495, RA 101495, RA101495, ZILUCOPLAN — per NCIT

Also identified as

Indications

Disease Relation Source
Myasthenia gravis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Musculature may treat a disease of this organ DERIVED · CC BY 4.0
Musculoskeletal system may treat a disease of this organ DERIVED · CC BY 4.0
Nervous system may treat a disease of this organ DERIVED · CC BY 4.0
Peripheral nervous system may treat a disease of this organ DERIVED · CC BY 4.0

4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.